(Q34020238)

30 July 2017

1 reference

title

Pharmacogenetics of antimalarial drugs: effect on metabolism and transport (English)

1 reference

30 July 2017

0 references

Peter Gottfried Kremsner

4

object named as

Peter G Kremsner

1 reference

30 July 2017

José Pedro Gil

5

0 references

author name string

Reinhold Kerb

1

1 reference

30 July 2017

Richard Fux

2

1 reference

30 July 2017

Klaus Mörike

3

1 reference

30 July 2017

Christoph H Gleiter

6

1 reference

30 July 2017

Matthias Schwab

7

1 reference

30 July 2017

publication date

1 December 2009

1 reference

Lancet Infectious Diseases

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

12

1 reference

30 July 2017

page(s)

760-774

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

30 July 2017

1 reference

7 January 2021

Drug-resistant malaria - an insight

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Transporters involved in resistance to antimalarial drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Effectiveness of antimalarial drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Antimalarial dosing regimens and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

The role of membrane transporters in drug delivery to brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Clinically available pharmacogenomics tests

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Pharmacogenetics - five decades of therapeutic lessons from genetic diversity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Pharmacokinetic interactions of antimalarial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

CYP2C19 polymorphism and proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

CYP2C8 polymorphism frequencies among malaria patients in Zanzibar.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Genetic variability in CYP2A6 and the pharmacokinetics of nicotine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Implications of genetic polymorphisms in drug transporters for pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Genetic variants of the organic cation transporter 2 influence the disposition of metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Antimalarial Drug Toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

CYP2C8 and antimalaria drug efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Antimalarial combinations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Pharmacokinetics of intravenous amodiaquine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

The disposition of amodiaquine in man after oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Synergism between amodiaquine and its major metabolite, desethylamodiaquine, against Plasmodium falciparum in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Stereoselective pharmacokinetics of mefloquine in young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Primaquine revisited six decades after its discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

The multiple dose pharmacokinetics of proguanil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

A study of the factors affecting the metabolic clearance of quinine in malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Population pharmacokinetics of intramuscular quinine in children with severe malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Role of P glycoprotein in absorption of novel antimalarial drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Increased uptake of quinine into the brain by inhibition of P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

On the question of dose-dependent chloroquine elimination of a single oral dose

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Pharmacokinetics of chloroquine and some of its metabolites in healthy volunteers: a single dose study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Complete heart block in chronic chloroquine poisoning

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Direct binding of chloroquine to the multidrug resistance protein (MRP): possible role for MRP in chloroquine drug transport and resistance in tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Functional expression of mouse Mdr1 in an outer membrane permeability mutant of Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

On the question of interindividual variations in chloroquine concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Plasma chloroquine concentrations in young and older malaria patients treated with chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Concentrations of chloroquine and malaria parasites in blood in Nigerian children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Artemisinins target the SERCA of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Artemisinins: their growing importance in medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Are currently deployed artemisinins neurotoxic?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Clinical pharmacology of artemisinin-based combination therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Pharmacokinetics of artemisinin-type compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin--from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Oral artesunate dose-response relationship in acute falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisinin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Inhibition and induction of human cytochrome P450 enzymes: current status

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

The global portfolio of new antimalarial medicines under development.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Disposition of atovaquone in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Organic anion transporter family: current knowledge.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

In vitro metabolism of clindamycin in human liver and intestinal microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Clindamycin activity against chloroquine-resistant Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

In vitro and in vivo metabolism of pyronaridine characterized by low-energy collision-induced dissociation mass spectrometry with electrospray ionization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Characterization of human urinary metabolites of the antimalarial piperaquine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Effects of a high-fat meal on the relative oral bioavailability of piperaquine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Artemisinin Resistance in Plasmodium falciparum Malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Evidence of Artemisinin-Resistant Malaria in Western Cambodia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Human alpha-1-glycoprotein and its interactions with drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

Regression to the truth: replication of association in pharmacogenetic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970320-2

7 January 2021

10.1016/S1473-3099(09)70320-2

Identifiers

DOI

1 reference

30 July 2017

1 reference